Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
You may also be interested in...
Japan Earnings Highlights: Takeda, Astellas And Eisai
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.
Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.
Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.